Phenominer Database Results (14 results)

 
 
Table "column sort" updates the order of the bars in the chart.
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Time Value Experiment Notes Record ID Study ID
ACI/SegHsd percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 4 0.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84524 1178
COP percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 8 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84528 1178
LEW.1F percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 4 50.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84534 1178
PVG percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 8 0.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84531 1178
BN/OlaHsd percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 7 0.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84523 1178
F344/NHsd percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 3 0.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84526 1178
LEW.1WR1/WorBrm percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 4 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84532 1178
LEW.1N percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 12 0.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84535 1178
LEW.1AV1/Kini percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 6 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84536 1178
WF/NHsd percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 5 0.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84525 1178
PVG.1AV1 percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 4 25.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84530 1178
LEW/Han percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 18 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84527 1178
DA/ZtmKini percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 5 80.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84529 1178
LEW.1AR1/Ztm percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 4 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84533 1178